Epatiti e Retrovirus

DiaSorin offre test di screening e soluzioni diagnostiche con un’ampia gamma di strumenti, test specifici e altamente sensibili, basati su tecnologia ELISA (compreso il test Murex) e disponibili sui sistemi LIAISON®.
I test comprendono HIV-1/2, HTLV, Epatite A, B, C, D, sifilide e numerose altre malattie infettive.

LIAISON® XL MUREX HBsAg Quant

The LIAISON® XL MUREX HBsAg Quant assay uses chemiluminescence immunoassay (CLIA) technology for the quantitative determination of hepatitis B surface antigen (HBsAg) in human serum or plasma samples. The test has to be performed on the LIAISON® XL analyzers only.

LIAISON® HBsAg

The LIAISON® HBsAg assay uses chemiluminescent immunoassay (CLIA) technology for the qualitative determination of hepatitis B surface antigen (HBsAg) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer only.

HBsAg Confirmatory Test

The HBsAg Confirmatory Test is an in vitro neutralization assay for confirmation of the presence of hepatitis B surface antigen (HBsAg) in human serum and plasma samples found repeatedly reactive for HBsAg by LIAISON® XL MUREX HBsAg Quant or LIAISON® HBsAg.

LIAISON® XL murex Anti-HBs

The LIAISON® XL Anti-HBs II assay uses chemiluminescence immunoassay (CLIA) technology for the quantitative determination of antibody to hepatitis B surface antigen (anti-HBs) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.

LIAISON® XL murex Anti-HBs Plus

The LIAISON® XL Anti-HBs II assay uses chemiluminescence immunoassay (CLIA) technology for the quantitative determination of antibody to hepatitis B surface antigen (anti-HBs) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.

LIAISON® Anti-HBc

The LIAISON® Anti-HBc assay uses chemiluminescent immunoassay (CLIA) technology for the qualitative determination of total antobodies to hepatitis B core antigen (anti-HBc) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.

LIAISON® HBc IgM

The LIAISON® HBc IgM assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of IgM immunoglobulim to hepatitis B core antigen (IgM anti-HBc) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.

LIAISON® HBeAg

The LIAISON® HBeAg assay uses chemiluminescent immunoassay (CLIA) technology for the quantitative determination of e antigen of hepatitis B virus (HBeAg) in human serum or plasma samples. HBeAg quantification may allow follow up of replicative activity/response to treatment (e.g. interferon) (20). The test has to be performed on the LIAISON® analyzer family.

LIAISON® Anti-HBe

The LIAISON® Anti-HBe assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of total antibodies to hepatitis B a antigen (anti-Bbe) in human serum or plasma samples. The test had to be perfomed on the LIAISON® analyzer family.

LIAISON® Anti-HAV

The LIAISON® Anti-HAV assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of total antibodies to hepatitis A virus (anti-HAV) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.

LIAISON® HAV IgM

The LIAISON® HAV IgM assay uses chemiluminescent immunoassay (CLIA) technology for the qualitative determination of IgM immunoglobulin to hepatitis A virus (IgM anti-HAV) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.

LIAISON® XL MUREX HCV Ab

The LIAISON® XL MUREX HCV Ab assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of specific antibodies to hepatitis C virus (anti-HCV) in human serum or plasma samples. The test has to be performed on the LIAISON® XL analyzers only.

LIAISON® XL MUREX HIV Ab / Ag

The LIAISON® XL MUREX HIV Ab / Ag assay uses chemiluminescence immunoassay (CLIA) technology for the combined qualitative determination of p24 antigen of human immunodeficiency virus type 1 (HIV-1) and specific antibodies to both human immunodeficiency virus type 1 (group M and group O) and/or human immunodeficiency virus type 2 (HIV-2) in human serum or plasma samples. The test has to be performed on the LIAISON® XL analyzers only.

LIAISON® XL MUREX HIV Ab/Ag HT

The LIAISON® XL murex HIV Ab / Ag HT assay uses chemiluminescence immunoassay (CLIA) technology for the combined qualitative determination of p24 antigen of human immunodeficiency virus type 1 (HIV-1) and specific antibodies to both human immunodeficiency virus type 1 (group M and group O) and/or human immunodeficiency virus type 2 (HIV-2) in human serum or plasma samples.
The LIAISON® XL murex HIV Ab / Ag HT assay is intended to be used as an aid in the diagnosis of HIV-1/HIV-2 infection and as a screening test for donated blood and plasma.
The test has to be performed on the LIAISON® XL Analyzer only.

LIAISON® XL recHTLV-I/II

The LIAISON® XL MUREX recHTLV-I/II assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of specific antibodies to Human T-cell Lymphotropic Virus (HTLV) type I and type II (anti-HTLV-I and anti-HTLV-II) in human serum or plasma samples.
The test has to be performed on the LIAISON® XL analyzer only.

 

Discover LIAISON® XL Hepatitis and Retrovirus
Discover our panel for screening of organs, tissues and cells post-mortem donors

Download the flyer

LIAISON® XL MUREX Anti-HDV

The LIAISON® XL murex Anti-HDV assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative detection of total antibodies
to hepatitis D virus in human serum and plasma samples. The assay results, in conjunction with other laboratory results and clinical information,
are intended to be used as an aid in the diagnosis of HDV infection and as a screening test for organ and tissue donors.

Visit also http://hdv.diasorin.com/

Murex HBsAg Version 3

Enzyme immunoassay for the detection of hepatitis B surface antigen in human serum or plasma.

Murex HBsAg Confirmatory Version 3

For the confirmation of the presence of hepatitis B surface antigen in human serum and plasma samples. To be used on serum or plasma samples found to be reactive in the Murex HBsAg Version 3 (9F80) assay.

Murex anti-HBc (total)

Enzyme immunoassay for the detection of antibodies to hepatitis B core antigen (anti-HBc) in human serum or plasma.

Murex anti-HCV (version 4.0)

An enzyme immunoassay for the detection of antibodies to hepatitis C virus (HCV) in human serum or plasma.

Murex HCV Ag/Ab Combination

Immunoassay for the simultaneous detection of hepatitis C (HCV) core antigen and anti-HCV antibodies in human serum or plasma.

Murex HIV Ag/Ab Combination

Enzyme immunoassay for improved detection of seroconversion to human immunodeficiency virus types 1 (HIV-1, HIV-1 group O) and detection of anti-HIV-2 antibodies in human serum or plasma.

Murex HIV-1.2.O

Enzyme immunoassay for the detection of antibodies to human immunodeficiency virus types 1 (HIV-1, HIV-1 group O) and 2 (HIV-2) in human serum or plasma.

Murex HTLV I + II

A qualitative enzyme immunoassay for the detection of antibodies against human T-lymphotropic virus types I and II (HTLV-I and HTLV-II) in human serum and plasma.

ICE* Syphilis

Enzyme immunoassay for the detection of antibodies against Treponema pallidum in human serum and plasma.

Discover ELISA Murex Menu

Download the Brochure

ETI-AB-HAVK PLUS (anti-HAV)
ETI-HA-IGMK PLUS (HAV IgM)
Murex HBsAg Version 3
Murex HBsAg Version 3 Confirmatory
ETI-AB-AUK-3 (anti-HBs)
Murex Anti-HBc (Total)
ETI-AB-COREK PLUS (anti-HBc)
ETI-CORE-IGMK PLUS (anti-HBc IgM)
ETI-AB-EBK PLUS (anti-HBe)
ETI-EBK PLUS (HBeAg)
Murex anti-HCV (version 4.0)
Murex HCV Ag/Ab Combination
HCV Blot 3.0** (anti-HCV)
ETI-AB-DELTAK-2 (anti-HD)
ETI-DELTAK-2 (HDAg)
ETI-DELTA-IGMK-2 (IgM anti-HD)
Anti-HEV IgG **
Anti-HEV IgM **
Murex HIV Ag/Ab Combination (HIV Ag/Ab)
Murex HIV 1.2.O (anti-HIV-1/2)
HIV Blot 2.2** (anti-HIV-1/2)
HIV-1 BLOT 1.3** (anti-HIV-1)
HIV-2 BLOT 1.2** (anti-HIV-2)
Murex HTLV I+II
HTLV BLOT 2.4** (anti-HTLV-I/II)
ICE* Syphilis
CHAGAS (Tripanosoma cruzi) IgG**
ELISA CHAGAS III**

 

L’epatite virale è una delle principali malattie in termini di morbidità e mortalità. In molti casi, l’epatite è una malattia non discriminante e selettiva a limitati gruppi geografici o sociali e non legata a fattori socio-economici. Per queste ragioni, è necessario che tutte le figure sanitarie sappiano come diagnosticare e monitorare l’epatite virale. In tutto il mondo, circa 150 milioni di persone sono affette da infezione cronica dal virus dell’Epatite C, circa 2 miliardi (secondo le stime) sono state infettate dal virus dell’Epatite B, mentre l’Epatite A colpisce 1,4 milioni di persone ogni anno.
I retrovirus includono il ben noto virus dell’immunodeficienza (HIV) e gli HTLV-I e II (virus I e II della leucemia umana a cellule T).
Quasi la metà delle persone infette da HIV non ne è a conoscenza finché non viene loro diagnosticato l’AIDS. Pertanto, l’identificazione precoce degli individui HIV positivi, il monitoraggio della carica virale e i test di resistenza, possono migliorare la condizione del paziente e ridurre la possibilità di trasmissione della malattia. Circa 34 milioni di persone sono HIV positive.
I test di laboratorio sono, perciò, essenziali per fornire ai sanitari gli strumenti necessari per una gestione migliore dei pazienti.
Ogni anno nel mondo si raccolgono circa 92 milioni di donazioni di sangue: oggi è possibile garantire la qualità e la sicurezza delle terapie trasfusionali grazie ad appropriate linee guida e ad un sistema di emovigilanza che controlla e migliora la sicurezza dei processi trasfusionali e dei test eseguiti in relazione alle malattie infettive trasmissibili con il sangue, come l’HIV, HCV, HBV, sifilide, e in alcuni paesi, la malattia di Chagas e HTLV I/II.